Table 1.

Baseline Characteristics of Studies that Met the Inclusion and Exclusion Criteria, Selected through a Systematic Screening Process from electronic databases. The table provides detailed information on study design, country of origin, sample size, gender distribution, age range, Child-Pugh classification, ECOG performance status, BCLC staging, and disease etiology (viral and non-viral).

Study, Year	Study Design	Country	Drug	Number of Sample	Male (N)	Female (N)	Age		Child-Pugh class: A/B		ECOG score: 0–1/2		BCLC		Etiology		NOS
							Range Age	Mean	A	B	0	>0	B	C	Viral	Non-viral
Kudo, 2018[18]	RCT	Italy	Lenvatinib	478	405	73	49.6-73	61.3	475	3	304	174	104	374	342	136	-
			Sorafenib	476	401	75	49.2-73.2	61.2	471	5	301	175	92	384	354	122
Burgio, 2021[20]	Prospective	Italy	Lenvatinib	144	111	33	N/A	N/A	137	7	114	30	36	108	101	43	7
			Sorafenib	144	119	25	N/A	N/A	134	10	114	30	36	108	89	55
Gardini, 2020[21]	Prospective	Italy	Lenvatinib	385	314	71	62.1-82-1	72.1	347	38	318	67	210	175	222	163	7
			Sorafenib	552	42	510	51.1-74.1	62.6	489	63	266	286	69	483	405	147
Nakano, 2020[22]	Prospective	Japan	Lenvatinib	146	125	21	63.2-82.4	72.8	134	12	N/A	N/A	79	67	102	44	9
			Sorafenib	146	121	25	64.3-81.3	72.8	137	9	N/A	N/A	81	65	105	41
Tomonari, 2020[23]	Retrospective	Japan	Lenvatinib	52	36	16	53–88	70	27	25	38	14	27	25	33	19	8
			Sorafenib	52	35	17	43-85	71	27	25	37	15	29	23	29	23
Kuzuya, 2020[24]	Retrospective	Japan	Lenvatinib	13	11	2	70	53-92	8	5	12	1	N/A	N/A	4	9	8
			Sorafenib	13	11	2	69	60-78	7	6	8	5	N/A	N/A	16	28
Kim, 2020[25]	Retrospective	Korea	Lenvatinib	44	39	5	N/A	51.0-66.3	36	8	41	3	N/A	N/A	N/A	N/A	8
			Sorafenib	61	51	10	N/A	58.0-70.5	56	5	59	2	N/A	N/A	N/A	N/A
Rimini, 2021[26]	Prospective	Italy	Lenvatinib	92	75	17	N/A	N/A	87	5	70	22	36	56	56	36	7
			Sorafenib	92	81	11	N/A	N/A	85	7	65	27	36	56	56	36
Vogel, 2021[19]	RCT	German	Lenvatinib	468	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-
			Sorafenib	463	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A